SEC Comment Letter for Cellectar Biosciences, Inc. (CLRB) (CIK 0001279704) (CLRB) — Aug 3, 2017
Cellectar Biosciences, Inc. (CLRB) (CIK 0001279704)
Date: Aug. 3, 2017 · CIK: 0001279704 · Accession: 0000000000-17-027396
AI Filing Summary & Sentiment
Reasoning
Letter
August 3, 2017 Chad Kolean Vice President and Chief Financial Officer Cellectar Biosciences, Inc. 3301 Agriculture Drive Madison, WI 53716 Cellectar Biosciences, Inc. Preliminary Proxy Statement on Schedule 14A Filed July 26, 2017 File No. 001-36598Re: Dear Mr. Kolean: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff. Division of Corporation Finance Office of Healthcare & Insurance cc: Sarah Fortt, Vinson & Elkins LLP
Show Raw Text
August 3, 2017 Chad Kolean Vice President and Chief Financial Officer Cellectar Biosciences, Inc. 3301 Agriculture Drive Madison, WI 53716 Cellectar Biosciences, Inc. Preliminary Proxy Statement on Schedule 14A Filed July 26, 2017 File No. 001-36598Re: Dear Mr. Kolean: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff. Division of Corporation Finance Office of Healthcare & Insurance cc: Sarah Fortt, Vinson & Elkins LLP